Related Experiment Video
Updated: Aug 4, 2026
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Advancing perspectives on prostate cancer: multihormonal influences in pathogenesis
A Porter1, E Ben-Josef, E D Crawford
1Department of Radiation Oncology, Wayne State University, Detroit, Michigan, USA. ceo@dmc.org
Molecular Urology
|January 16, 2002
Summary
Nonandrogenic hormones, particularly follicle-stimulating hormone (FSH), play a role in prostate cancer. Prostatic inhibin peptide (PIP) interacts with FSH, influencing prostate cell function and disease progression.
Area of Science:
- Endocrinology
- Oncology
- Urology
Background:
- The prostate gland functions as an endocrine organ, producing hormones and growth factors.
- Nonandrogenic hormones, including follicle-stimulating hormone (FSH), are increasingly recognized for their role in prostate health and disease.
- Elevated FSH levels and receptor expression in prostate cancer tissues suggest its involvement in tumorigenesis.
Purpose of the Study:
- To explore the role of nonandrogenic hormones, specifically FSH and prostatic inhibin peptide (PIP), in prostate cancer.
- To investigate the intricate relationship between FSH and PIP in regulating prostate cell function.
- To highlight other endocrine factors relevant to prostate cancer management.
Main Methods:
- Review of existing endocrinologic research on prostate cancer.
- Analysis of findings related to FSH concentrations and receptor expression in diseased prostate tissue.
- Examination of the interplay between FSH and PIP in prostate cells.
Main Results:
- Increased FSH concentrations and receptor expression are observed in diseased prostate tissue.
- Prostatic inhibin peptide (PIP) suppresses circulating FSH and modulates prostatic FSH, indicating a significant interlinkage.
- This FSH-PIP axis appears crucial for controlling both healthy and diseased prostate cells.
Conclusions:
- FSH and PIP represent key nonandrogenic hormonal factors implicated in prostate cancer growth and function.
- Understanding the FSH-PIP axis offers potential new therapeutic targets for prostate cancer.
- Further research is needed to resolve optimal timing, administration, and multihormonal approaches for prostate cancer management.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...